Jeremy Segal to Protein Kinase Inhibitors
This is a "connection" page, showing publications Jeremy Segal has written about Protein Kinase Inhibitors.
Connection Strength
0.160
-
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017 Aug 01; 23(15):4212-4223.
Score: 0.105
-
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. Clin Cancer Res. 2019 02 15; 25(4):1174-1184.
Score: 0.029
-
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
Score: 0.026